At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HCWB HCW Biologics Inc.
Closed 11-21 16:00:00 EST
0.7096
-0.2376
-25.08%
盘后0.7095
-0.0001-0.01%
19:58 EST
High0.8694
Low0.6950
Vol3.96M
Open0.8623
D1 Closing0.9472
Amplitude18.41%
Mkt Cap26.84M
Tradable Cap12.67M
Total Shares37.82M
T/O3.07M
T/O Rate22.21%
Tradable Shares17.85M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
HCW Biologics Expands with New Financial Agreements
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. The company was incorporated in 2018 and is headquartered in Miramar, Florida.